放化疗诱导肿瘤细胞死亡与肿瘤再增殖的研究进展

doi:10.12280/gjfckx.20240767

摘要/Abstract

摘要：

肿瘤再增殖是指癌症治疗后残存肿瘤细胞的增殖现象，是导致治疗失败和肿瘤复发的重要原因。放化疗后肿瘤的再增殖机制极为复杂，通常与放化疗诱导的肿瘤细胞死亡有关。放疗或化疗后，肿瘤细胞可能通过凋亡、坏死、自噬或焦亡等多种方式死亡。研究表明，这些不同的死亡方式可能与残存肿瘤细胞的再增殖相关。一方面，它们可能通过调节下游特定的信号通路直接影响残存肿瘤细胞的增殖；另一方面，它们可能通过改变肿瘤微环境中的肿瘤相关成纤维细胞、免疫细胞、内皮细胞等多种细胞的功能，进而重塑肿瘤微环境，为残存肿瘤细胞的增殖和转移创造条件。本文综述了放化疗后肿瘤细胞的死亡与残存肿瘤细胞再增殖之间的关系，并从细胞死亡方式与肿瘤微环境等多个角度分析治疗后肿瘤再增殖的可能机制，以期为预防癌症复发提供策略。

关键词: 细胞死亡, 肿瘤再增殖, 肿瘤微环境, 癌相关成纤维细胞, 免疫细胞, 内皮细胞

Abstract:

Tumor repopulation is the phenomenon of proliferation of residual tumor cells after cancer treatment, which is an important cause of treatment failure and tumor recurrence. The mechanism of tumor repopulation after radiotherapy or chemotherapy is extremely complex and is usually related to chemoradiotherapy-induced tumor cell death. After radiotherapy or chemotherapy, tumor cells may die in a variety of ways, including apoptosis, necrosis, autophagy, or pyroptosis. Studies have shown that tumor cell death may be associated with the tumor repopulation. On the one hand, they may directly affect the proliferation of residual tumor cells by regulating specific downstream signaling pathways. On the other hand, they may alter the functions of cancer-associated fibroblasts, immune cells, endothelial cells and other cells in the tumor microenvironment, then remodeling the tumor microenvironment in order to create conditions for the proliferation and metastasis of residual tumor cells. In this paper, we reviewed the relationship between tumor cell death and the repopulation of residual tumor cells after radiotherapy or chemotherapy, and analyzed the possible mechanisms of tumor repopulation from multiple perspectives, such as the mode of cell death and the tumor microenvironment, which is expected to provide a strategy for the prevention of cancer recurrence.

Key words: Cell death, Tumor repopulation, Tumor microenvironment, Cancer-associated fibroblasts, Immune cell, Endothelial cells

陈志茹, 戴岚. 放化疗诱导肿瘤细胞死亡与肿瘤再增殖的研究进展[J]. 国际妇产科学杂志, 2024, 51(6): 648-653.

CHEN Zhi-ru, DAI Lan. Research Progress of the Relationship between Chemoradiotherapy-Induced Tumor Cell Death and Tumor Repopulation[J]. Journal of International Obstetrics and Gynecology, 2024, 51(6): 648-653.

参考文献 32

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi: 10.3322/caac.21834.
[2]	Cheng J, He S, Wang M, et al. The Caspase-3/PKCδ/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy[J]. Clin Cancer Res, 2019, 25(12):3732-3743. doi: 10.1158/1078-0432.CCR-18-3001. pmid: 30890550
[3]	Corsi F, Capradossi F, Pelliccia A, et al. Apoptosis as Driver of Therapy-Induced Cancer Repopulation and Acquired Cell-Resistance (CRAC): A Simple In Vitro Model of Phoenix Rising in Prostate Cancer[J]. Int J Mol Sci, 2022, 23(3):1152. doi: 10.3390/ijms23031152.
[4]	Ling R, Wang J, Fang Y, et al. HDAC-an important target for improving tumor radiotherapy resistance[J]. Front Oncol, 2023, 13:1193637. doi: 10.3389/fonc.2023.1193637.
[5]	Cui L, Zhao Y, Pan Y, et al. Chemotherapy induces ovarian cancer cell repopulation through the caspase 3-mediated arachidonic acid metabolic pathway[J]. Onco Targets Ther, 2017, 10:5817-5826.doi: 10.2147/OTT.S150456.Erratum in: Onco Targets Ther, 2022, 15:1503-1504. doi: 10.2147/OTT.S397709.
[6]	Feng X, Zhu F, Dai L, et al. Caspase-3 in glioma indicates an unfavorable prognosis by involving surrounding angiogenesis and tumor cell repopulation[J]. J Neurooncol, 2023, 163(2):313-325. doi: 10.1007/s11060-023-04339-x.
[7]	Li F, Huang Q, Chen J, et al. Apoptotic cells activate the "phoenix rising" pathway to promote wound healing and tissue regeneration[J]. Sci Signal, 2010, 3(110):ra13. doi: 10.1126/scisignal.2000634.
[8]	Asadi M, Taghizadeh S, Kaviani E, et al. Caspase-3: Structure, function, and biotechnological aspects[J]. Biotechnol Appl Biochem, 2022, 69(4):1633-1645. doi: 10.1002/bab.2233.
[9]	Zhao Y, Cui L, Pan Y, et al. Berberine inhibits the chemotherapy-induced repopulation by suppressing the arachidonic acid metabolic pathway and phosphorylation of FAK in ovarian cancer[J]. Cell Prolif, 2017, 50(6):e12393. doi: 10.1111/cpr.12393.
[10]	Zhang F, Jia Y, Zheng X, et al. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence[J]. Acta Biomater, 2019, 100:352-364. doi: 10.1016/j.actbio.2019.09.034. pmid: 31563690
[11]	Yu Y, Tian L, Feng X, et al. eIF4E-phosphorylation-mediated Sox2 upregulation promotes pancreatic tumor cell repopulation after irradiation[J]. Cancer Lett, 2016, 375(1):31-38. doi: 10.1016/j.canlet.2016.02.052. pmid: 26945967
[12]	Brina D, Ponzoni A, Troiani M, et al. The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells[J]. Nat Cancer, 2023, 4(8):1102-1121. doi: 10.1038/s43018-023-00594-z.
[13]	Fan A, Gao M, Tang X, et al. HMGB1/RAGE axis in tumor development: unraveling its significance[J]. Front Oncol, 2024, 14:1336191. doi: 10.3389/fonc.2024.1336191.
[14]	Wang Y, Zhao M, He S, et al. Necroptosis regulates tumor repopulation after radiotherapy via RIP1/RIP3/MLKL/JNK/IL8 pathway[J]. J Exp Clin Cancer Res, 2019, 38(1):461. doi: 10.1186/s13046-019-1423-5. pmid: 31706322
[15]	Lin P, Lin C, He R, et al. TRAF6 regulates the abundance of RIPK1 and inhibits the RIPK1/RIPK3/MLKL necroptosis signaling pathway and affects the progression of colorectal cancer[J]. Cell Death Dis, 2023, 14(1):6. doi: 10.1038/s41419-022-05524-y. pmid: 36604411
[16]	Zhang LQ, Sun L, Zhou YQ, et al. Pentacyclic triterpene-amino acid derivatives induced apoptosis and autophagy in tumor cells, affected the JNK and PI3K/AKT/mTOR pathway[J]. Bioorg Med Chem, 2023, 94:117478. doi: 10.1016/j.bmc.2023.117478.
[17]	You B, Xia T, Gu M, et al. AMPK-mTOR-Mediated Activation of Autophagy Promotes Formation of Dormant Polyploid Giant Cancer Cells[J]. Cancer Res, 2022, 82(5):846-858. doi: 10.1158/0008-5472.CAN-21-2342.
[18]	Dai Z, Liu WC, Chen XY, et al. Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors[J]. Front Immunol, 2023, 14:1178662. doi: 10.3389/fimmu.2023.1178662.
[19]	Wang YL, Wu WR, Lin PL, et al. The Functions of PCNA in Tumor Stemness and Invasion[J]. Int J Mol Sci, 2022, 23(10):5679. doi: 10.3390/ijms23105679.
[20]	Avalle L, Raggi L, Monteleone E, et al. STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts[J]. Oncogene, 2022, 41(10):1456-1467. doi: 10.1038/s41388-021-02172-y. pmid: 35042959
[21]	Fang Z, Meng Q, Xu J, et al. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives[J]. Cancer Commun(Lond), 2023, 43(1):3-41. doi: 10.1002/cac2.12392.
[22]	Wang JQ, Dong Y, Feng ZM, et al. Ginsenoside Re Attenuates Cisplatin-Induced Intestinal Toxicity via Suppressing GSK-3β-Dependent Wnt/β-Catenin Signaling Pathway In Vivo and In Vitro[J]. Am J Chin Med, 2023, 51(2):407-424. doi: 10.1142/S0192415X23500210.
[23]	Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives[J]. Mol Cancer, 2021, 20(1):131. doi: 10.1186/s12943-021-01428-1. pmid: 34635121
[24]	Xiao L, Zhu H, Shu J, et al. Overexpression of TGF-β1 and SDF-1 in cervical cancer-associated fibroblasts promotes cell growth, invasion and migration[J]. Arch Gynecol Obstet, 2022, 305(1):179-192. doi: 10.1007/s00404-021-06137-0.
[25]	Suh J, Kim DH, Lee YH, et al. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling[J]. Mol Carcinog, 2020, 59(9):1028-1040. doi: 10.1002/mc.23233.
[26]	Ershaid N, Sharon Y, Doron H, et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis[J]. Nat Commun, 2019, 10(1):4375. doi: 10.1038/s41467-019-12370-8. pmid: 31558756
[27]	Sumitomo R, Menju T, Shimazu Y, et al. M2-like tumor-associated macrophages promote epithelial-mesenchymal transition through the transforming growth factor β/Smad/zinc finger e-box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamous cell carcinoma[J]. Cancer Sci, 2023, 114(12):4521-4534. doi: 10.1111/cas.15987.
[28]	Xu M, Zhou C, Weng J, et al. Tumor associated macrophages-derived exosomes facilitate hepatocellular carcinoma malignance by transferring lncMMPA to tumor cells and activating glycolysis pathway[J]. J Exp Clin Cancer Res, 2022, 41(1):253. doi: 10.1186/s13046-022-02458-3. pmid: 35986343
[29]	Basu A, Ramamoorthi G, Albert G, et al. Differentiation and Regulation of T(H) Cells: A Balancing Act for Cancer Immunotherapy[J]. Front Immunol, 2021, 12:669474. doi: 10.3389/fimmu.2021.669474.
[30]	Jiang Y, Yuan Y, Chen M, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression[J]. Theranostics, 2021, 11(18):9162-9176. doi: 10.7150/thno.59605. pmid: 34522232
[31]	Zhong N, Zhuang W, Huang Q, et al. Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki-67/CD31[J]. J Cell Mol Med, 2021, 25(21):10039-10048. doi: 10.1111/jcmm.16926. pmid: 34590406
[32]	Mou J, Li C, Zheng Q, et al. Research progress in tumor angiogenesis and drug resistance in breast cancer[J]. Cancer Biol Med, 2024, 21(7):571-585. doi: 10.20892/j.issn.2095-3941.2023.0515.